| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We have attempted to develop lecithin-modified proteins as improved therapeutic proteins (biobetters). Lysosome enzyme or IgG antibody was used as the protein, and its activity and interaction with cultured cells were analyzed. The lecithinized lysosomal enzyme had low cytotoxicity and formed a complex with plasma proteins. Furthermore, the enzyme was internalized in the cells, and showed high enzymatic activity. On the other hand, it was found that the lecithinized antibody can maintain the antigen-binding activity by reducing the amount of organic solvent during the synthetic reaction. This lecithinized antibody was more internalized in the cells than the unmodified antibody.
|
